Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RAD52 | P43351 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 2/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | UBE2M | P61081 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL272847 | 0.86 | NR1H2 (0.63) | NR1H2GAAGLAPOLBTSHR | |
| SCHEMBL12426571 | 0.85 | EPHX2 (0.44) | NR1H2EPHX2TSHRDDR1HRH3 | |
| SCHEMBL24192437 | 0.85 | NR1H2 (0.51) | NR1H2EPHX2GAAGLAPOLB | |
| SCHEMBL24192440 | 0.84 | NR1H2 (0.51) | NR1H2EPHX2DDR1ACHEHTR4 | |
| SCHEMBL2201169 | 0.83 | NR1H2 (0.49) | NR1H2GAAGLAPOLBTSHR | |
| SCHEMBL13632562 | 0.82 | RYR2 (0.44) | GAAMAPTRAD52GFERHRH3 | |
| SCHEMBL16380639 | 0.82 | DDR1 (0.47) | EPHX2GAADDR1EGFRBRAF | |
| SCHEMBL1279087 | 0.81 | NR1H2 (0.79) | NR1H2GAAGLAPOLBTSHR | |
| SCHEMBL16335699 | 0.80 | DDR1 (0.48) | EPHX2DDR1EGFRBRAFMEN1 | |
| SCHEMBL4929349 | 0.78 | NR1H2 (0.63) | NR1H2EPHX2GAAGLAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
| CN-101558068-A | Phenylacetamides useful as protein kinase inhibitors | NOVARTIS AG (CH) | 2009-10-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | FLT3, JAK2, ABL1 | NR1H2 2592/4885EPHX2 2955/4885GAA 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.